Grand Pharmaceutical (00512.HK): GPN01768 [TP-03, (Loteranal Eye Drops) 0.25%), a globally innovative ophthalmic drug introduced by the Group for the treatment of Demodex blepharitis, recently officially obtained a drug registration certificate issued by the National Medical Products Administration of the People's Republic of China. Moreover, no supplementary information was requested during the drug review process, achieving "zero supplementary information" approval for market launch.